Medication persistence among patients with asthma/COPD drugs
- 437 Downloads
Objective To determine medication possession ratio (MPR) of patients with asthma/COPD drugs. Method Individual patient’s volumes of asthma/COPD drugs (ATC-code R03) for 2000–2004 were obtained from a pharmacy record database. For each patient the MPR was calculated as the percentage of the treatment time that the patient had drugs available. Main outcome measure Medication possession ratio (MPR). Results A total of 1,812 patients, 20 years and older, with dispensed asthma/COPD drugs were registered in the database, 928 patients (51%) had acquired drugs less than once per year (68% for 20–29 years old) during the 5-year study. Only 13% of the patients had steroids and steroid combinations available to allow continuous treatment. Eight percent of the patients 20–29 years old had MPR ≥ 80% of all the included drugs and 5% when only steroids and steroid combinations were considered. About 25% of the patients had acquired 80% of the total volume of asthma/COPD drugs. Conclusion The majority of the patients, and particularly those in the youngest age group used asthma/COPD drugs only sporadically. This may indicate undermedication which is likely to have a negative impact on patient outcome.
KeywordsAdherence Asthma COPD Medication persistence Pharmacy records Sweden
Support from Apoteket AB and the Swedish Association of Senior Citizens (SPF) is gratefully acknowledged.
Financial support was obtained from Apoteket AB and the Swedish Association of Senior Citizens (SPF), Stockholm.
Conflict of interest
The authors have no conflict of interest to declare.
- 1.Adherence to long-term therapies. Evidence for action. WHO-report. WHO, Geneva 2003.Google Scholar
- 3.Haynes RB, Yao X, Degani A, Kriplani S, Garg A, McDonald HP. Interventions for enhancing medication adherence. The Cochrane Database of Systematic Reviews 2005, Issue 4. Art.No.:CD000011.pub2.DOI:10.1002/14651858.CD000011.pub2.Google Scholar
- 5.Ernst FR, Grizzle AJ. Drug-related morbidity and mortality: Updating the cost-of-illness model. J Am Pharm Assoc 2001;41:192–9.Google Scholar
- 15.Guidelines for ATC classification and DDD assignment 2006. WHO Collaborating Centre for Drug Statistics Methodology. Oslo, Norway. www.whocc.no.
- 17.Haupt D, Nilsson JLG. Defined daily doses (DDD) related to prescribed daily doses (PDD) for asthma/COPD drugs in Sweden. WHO Drug Info. 2006;20:261–4.Google Scholar
- 20.Nilsson JLG, Johansson H, Wennberg M. Large differences between prescribed and dispensed medicines could indicate undertreatment. Drug Inf J. 1995;29:1243–6.Google Scholar
- 24.Lindström M, Jönsson E, Larsson K, Lundbäck B. Underdiagnosing of obstructive lung disease in northern Sweden. Int J Tuberc Lung Dis. 2002;6:78–84.Google Scholar